Related Experiment Video
Updated: Jan 27, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Caspase-1 Inhibition Attenuates Hyperoxia-induced Lung and Brain Injury in Neonatal Mice
Fredrick Dapaah-Siakwan1,2, Ronald Zambrano1,2, Shihua Luo1,2
1Division of Neonatology and.
Insights
Hyperoxia causes lung and brain injury in preterm infants by activating the inflammasome. Inhibiting caspase-1 (a key inflammasome component) protected against this injury, suggesting a potential therapeutic target.
Area of Science:
- Neonatal physiology
- Inflammation and immunology
- Developmental neuroscience
Background:
- Bronchopulmonary dysplasia (BPD) in preterm infants is linked to hyperoxia and neurodevelopmental impairment.
- The mechanisms underlying BPD-induced brain injury are not fully understood.
- Previous research linked hyperoxia-induced BPD in rodents to lung inflammasome activation.
Purpose of the Study:
- To test if inflammasome activation mediates hyperoxia-induced lung and brain injury in neonatal mice.
- To investigate if inhibiting caspase-1 (a key inflammasome component) can reduce this injury.
Main Methods:
- Neonatal mice were exposed to room air or hyperoxia (85% O2) for 10 days.
- Mice received daily injections of a caspase-1 inhibitor (Ac-YVAD-CMK) or placebo.
- Lung and brain tissues were analyzed for inflammasome activation (NLRP1, IL-1β, GSDMD) and injury markers.
Main Results:
- Hyperoxia activated the NLRP1 inflammasome, increasing mature IL-1β and active gasdermin-D (GSDMD) in both lung and brain.
- Caspase-1 inhibition reduced IL-1β and GSDMD activation.
- Inhibition improved lung alveolar and vascular development and promoted cell proliferation in key brain regions, reducing atrophy.
Conclusions:
- The inflammasome pathway is critical in hyperoxia-induced neonatal lung and brain injury.
- Targeting caspase-1 may offer a protective strategy against BPD-related neurodevelopmental impairments in preterm infants.
Abstract:
Hyperoxia plays a key role in the development of bronchopulmonary dysplasia (BPD), a chronic lung disease of preterm infants. Infants with BPD often have brain injury that leads to long-term neurodevelopmental impairment, but the underlying mechanisms that control BPD-induced neurodevelopmental impairment remain unclear. Our previous studies have shown that hyperoxia-induced BPD in rodents is associated with lung inflammasome activation. Here, we tested the hypothesis that hyperoxia-induced lung and brain injury is mediated by inflammasome activation, and that inhibition of caspase-1, a key component of the inflammasome, attenuates hyperoxia-induced lung and brain injury in neonatal mice. C57/BL6 mouse pups were randomized to receive daily intraperitoneal injections of Ac-YVAD-CMK, an irreversible caspase-1 inhibitor, or placebo during exposure to room air or hyperoxia (85% O2) for 10 days. We found that hyperoxia activated the NLRP1 inflammasome, increased production of mature IL-1β, and upregulated expression of p30 gasdermin-D (GSDMD), the active form of GSDMD that is responsible for the programmed cell death mechanism of pyroptosis in both lung and brain tissue. Importantly, we show that inhibition of caspase-1 decreased IL-1β activation and p30 GSDMD expression, and improved alveolar and vascular development in hyperoxia-exposed lungs. Moreover, caspase-1 inhibition also promoted cell proliferation in the subgranular zone and subventricular zone of hyperoxia-exposed brains, resulting in lessened atrophy of these zones. Thus, the inflammasome plays a critical role in hyperoxia-induced neonatal lung and brain injury, and targeting this pathway may be beneficial for the prevention of lung and brain injury in preterm infants.
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Caspases
Feedback Inhibition
Lung Capacity
Enzyme Inhibition
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

